| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |